eFoodSafety.com, Inc.'s Cinnergen(TM) to be Featured on ABC's ''Eyewitness News Sunday Morning''

eFoodSafety.com, Inc. (OTCBB:EFSF) announced today that Cinnergen™, the company’s clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism, will be featured in a segment on diabetes on ABC’s "Eyewitness News Sunday Morning”. The show will be hosted by Michelle Charlesworth and Phil Lipof and will be broadcast from New York. The segment will air within the 8:45-9:30am time slot on Sunday, November 11, 2007. The segment will also be featured at www.7online.com. Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "We’re extremely pleased to have our Cinnergen™ featured as a part of this important segment on diabetes. There are over 20 million confirmed diabetics in the US alone, with one-third of that total being undiagnosed. It is estimated that three times that number of people are pre-diabetic. There are millions more who have blood sugar imbalances and are unaware of their condition, and millions more that are insulin resistant, which is a strong indicator of future diabetes.” Cinnergen™ is available for purchase at www.cinnergen.com, as well as other national retail outlets. About eFoodSafety.com, Inc. eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company’s Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) – EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The OraPhyte™ product which has been tested and shown to be effective at eradicating nematodes by the U.S. Department of Agriculture is currently at three major universities with outstanding Agricultural Departments undergoing crop-specific research. The company’s MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn™-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn™ line. The Company is also owner of Cinnergen™, a clinically-studied, non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com) and Cinnechol™, a multi-faceted nutritional supplement specifically designed to naturally reduce total cholesterol levels without causing any side effects. The Company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect™ anti-acne skin care system. Please visit the Company’s website at: http://www.efoodsafety.com. Safe Harbor Forward-Looking Statements Statements contained in this release that are not strictly historical are "forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. The forward-looking statements are made based on information available as of the date hereof, and the Company assumes no obligation to update such forward-looking statements. Editors and investors are cautioned that such forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from those in these forward-looking statements. Such risks and uncertainties include but are not limited to demand for the Company’s products and services, our ability to continue to develop markets, general economic conditions, our ability to secure additional financing for the Company and other factors that may be more fully described in reports to shareholders and periodic filings with the Securities and Exchange Commission.